×
Josh Mathew

Josh Mathew

Vice President - Product Innovation & Strategy

Josh is the Vice President of Product Innovation and Strategy at Slayback Pharma. In this role he will help build a portfolio that will deliver innovative products that meet the evolving needs of the marketplace. He has over 19 years of experience starting with Pharmaceutical Development at Merck Research Laboratories and most recently Global Commercial Lead for Lifecyle Management at Pfizer. Josh holds a BE in Chemical Engineering, MS in Pharmaceutics and an MBA in Corporate Innovation and Leadership from Stevens Institute of Technology.

Copyright ©2021 all rights reserved

Hydroxyprogesterone

On April 6, 2023, the U.S. Food and Drug Administration (FDA) issued a final decision ordering the withdrawal of the approval of Makena® (hydroxyprogesterone caproate injection, 250 milligrams (mg) per mL) and its generics. FDA recognizes that there is a supply of product that has already been distributed. Patients who have questions should talk to their healthcare provider. We recommend health care practitioners consider FDA’s conclusions.

If you have questions or concerns about receiving your therapy as prescribed, consult your healthcare provider.

https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena